A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 28 Jun 2018
At a glance
- Drugs OMO-1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Octimet Oncology
- 22 Jun 2018 Planned number of patients changed from 80 to 220.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.